In a statement, Nxera CEO Chris Cargill said Kaneko’s appointment will help the company “maximize our commercial activities ...

British pharmaceutical giant AstraZeneca announced on Friday that it will invest $2.5 billion in a research and development center in Beijing, China.

AstraZeneca Plc’s experimental cholesterol drug significantly reduced “bad” cholesterol in a mid-stage trial, boosting hopes for a potential blockbuster that could be part of a powerful ...

1. AstraZeneca to invest $2.5 billion in new global strategic R&D centre, biotech agreements and manufacturing in Beijing.

The new centre will focus on early-stage research and clinical development, supported by data science and AI labs.

Beijing: AstraZeneca has announced an investment of USD 2.5 billion in Beijing to establish its sixth global strategic R&D ...